COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
United States, Nevada, Las Vegas, DelveInsight’s “Retinal Vein Occlusion – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Retinal Vein Occlusion market share of the individual therapies, current and forecasted Retinal Vein Occlusion market size from 2019 to 2032 segmented by seven major markets. The report also offers current Retinal Vein Occlusion therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Retinal Vein Occlusion market.
Retinal Vein Occlusion Overview
Retinal vein occlusion is one of the most frequently occurring retinal vascular disorders in elderly patients that develop predominantly in individuals over the age of 65 years. The main risk factor for Retinal vein occlusion includes age. With the increase of the geriatric population, as of now, the prevalence of retinal vein occlusion is also supposed to be on the high rise.
Retinal Vein Occlusion Epidemiological Insights
Among EU-5 countries, the highest number of prevalent cases of Retinal vein occlusion were in Germany, (approximately 225,397 cases), in the year 2021, which are expected to increase by 2032. The lowest number of cases were observed in Spain.
Retinal Vein Occlusion Treatment Market
The current treatment options for Retinal vein occlusion intend to minimize the damage, as there is no treatment to improve vision loss in the long term. The therapies aim to prevent further visual loss and its complications, such as macular edema, ischemia, or neovascularization.
The mainstay treatment for Retinal vein occlusion includes intravitreal injection of anti-VEGF drugs. These drugs target VEGF, an important growth factor that causes macular edema. Intravitreal injection of corticosteroid drugs is to combat inflammation and edema. Intraocular injections of steroids are another potential treatment for eyes that do not respond to anti-VEGF drugs. While intraocular steroids can have some side effects such as an increase in eye pressure and cataract progression, in most cases, these side effects can be controlled.
Promising Therapies in the Retinal Vein Occlusion Pipeline
Discover more about Retinal Vein Occlusion therapies in the pipeline @ Retinal Vein Occlusion Drugs
Leading Companies Working in the Retinal Vein Occlusion Market
To understand key companies related to the Retinal Vein Occlusion Market, get a snapshot of the Retinal Vein Occlusion Regulatory and Patent Analysis.
Scope of the Retinal Vein Occlusion Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Retinal Vein Occlusion Companies: Roche, AbbVie, Kodiak Sciences, Roche, Chugai Pharmaceuticals, Taiwan Liposome Company, and others
Key Retinal Vein Occlusion Pipeline Therapies: Lucentis (ranibizumab), Ozurdex (dexamethasone), KSI-301, Vabysmo (faricimab), TLC399 (ProDex), and others
Therapeutic Assessment: Retinal Vein Occlusion current marketed and emerging therapies
Retinal Vein Occlusion Market Dynamics: Retinal Vein Occlusion market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Retinal Vein Occlusion Market Access and Reimbursement
Table of Contents
Leading Reports by DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187